SignalEU/UK
Alamar Biosciences, Inc. (ALMR) Presents at 2026 UBS Global Healthcare Conference Transcript
High-priority alert based on source significance and keyword relevance.
Context
What happened: Alamar Biosciences CFO Justin McAnear presented at the 2026 UBS Global Healthcare Conference, where UBS analyst Doug Schenkel noted the company's recent quarterly results, a collaboration with the U.K. Biobank and GSK, and a raised 2026 revenue outlook.
Key numbers: Revenue up 68%. Consumables up 79%. Gross margin reached a record 61.5%.
Why it matters: The analyst framed the discussion around durable growth driven by improved installed base economics, content expansion, and a more pronounced move into diagnostics.
What changed
Alamar Biosciences CFO Justin McAnear presented at the 2026 UBS Global Healthcare Conference, where UBS analyst Doug Schenkel noted the company's recent quarterly results, a collaboration with the U.K. Biobank and GSK, and a raised 2026 revenue outlook.
Why it matters
The analyst framed the discussion around durable growth driven by improved installed base economics, content expansion, and a more pronounced move into diagnostics.